Hany Ashamalla, MD
Psychiatry · Surprise, AZNPI 1255645891
Payments from drug & device makers
Across 89 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lundbeck LLC$338
- AbbVie$181
- Otsuka America Pharmaceutical, Inc.$157
- Johnson & Johnson$155
- Sunovion Pharmaceuticals Inc.$131
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$124
- plus $691 from 13 others
What the payments were for
- Food & beverage$1,74698%
- Education$302%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lundbeck LLC | 14 | $338 |
| AbbVie(2 entities) | 11 | $181 |
| Otsuka America Pharmaceutical, Inc. | 7 | $157 |
| Johnson & Johnson | 7 | $155 |
| Sunovion Pharmaceuticals Inc. | 11 | $131 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $124 |
| Alkermes, Inc. | 5 | $100 |
| Neurocrine Biosciences, Inc. | 3 | $89 |
| E.r. Squibb & Sons, L.L.C. | 4 | $82 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 3 | $68 |
| Bausch Health US, LLC | 4 | $64 |
| Eisai Inc. | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Indivior Inc. | 1 | $25 |
| Supernus Pharmaceuticals, Inc. | 1 | $19 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Merck | 1 | $14 |
How this compares
$1,776 in reported general payments places this provider in the 80th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Divalproex Sodium ErDivalproex Sodium | 45 | $1,842 |
| Divalproex Sodium | 37 | $1,444 |
| Quetiapine Fumarate | 58 | $1,323 |
| Trazodone Hcl | 172 | $1,130 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 80 | $910 |
| Risperidone | 68 | $778 |
| Bupropion XlBupropion Hcl | 60 | $703 |
| Escitalopram Oxalate | 70 | $631 |
| Bupropion Hcl | 20 | $617 |
| Aripiprazole | 32 | $550 |
| Olanzapine | 27 | $504 |
| Sertraline Hcl | 74 | $502 |
| Duloxetine Hcl | 37 | $486 |
| Oxcarbazepine | 11 | $434 |
| Gabapentin | 41 | $403 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Surprise
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Katherine KelleyChandler$610K
- Payam SadrMesa$487K
- Steven BuppTucson$451K
- Monica BenavidezPhoenix$435K
- Ahmed ElmaadawiPhoenix$395K
- Lee KelleyPhoenix$340K
- Bahar GolestanMesa$234K
- Shahzad AliTucson$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.